- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT04583657
Intestinal Tolerance & Health Effects of Daily Consumption of Two Eggs With Fatty Acid Profile Related to Metabolic Disorders (Oil4Egg)
To Evaluate the Intestinal Tolerance and Health Effects of Daily Consumption of Two Eggs With a Particular Fatty Acid Profile on a Set of Parameters Related to Metabolic Disorders
This study has two objectives: 1) to check that the daily consumption of two eggs with a particular fatty acid pattern rich in n-3 polyunsaturated fatty acids (α-linolenic acid, docosahexaenoic acid), conjugated-linoleic acid and conjugated-linolenic acid is well tolerated by the consumer ; 2) to evaluate the effects of the consumption of these eggs on health parameters in subjects presenting a risk of developing a metabolic disorder.
This monocentric study is an interventional, randomized, double-blind, control study.
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids show interesting effects in the context of health. Indeed, some studies suggest positive effects on circulating lipids or inflammation associated with certain disorders such as diabetes, following the consumption of these fatty acids.
However, these fatty acids are not very present in the classic diet. Therefore, we have developped hens eggs naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids by changing the hens feed.
This study has two objectives: 1) to check that the daily consumption of two eggs with a particular fatty acid pattern rich in n-3 polyunsaturated fatty acids (α-linolenic acid, docosahexaenoic acid), conjugated-linoleic acid and conjugated-linolenic acid is well tolerated by the consumer ; 2) to evaluate the effects of the consumption of these eggs on health parameters in subjects presenting a risk of developing a metabolic disorder.
To do this, 80 subjects aged 35 to 75, sedentary (<2 hours of physical activity per week) and with abdominal obesity (> 94cm for men and> 80cm for women) were recruited and were divided into two groups: the control group (12 subjects consuming 2 classic eggs for 3 months per day) or the test group (12 subjects consuming 2 eggs enriched in omega per day for 3 months).
A medical examination with blood sampling was scheduled every month at baseline (Day 0), after one month (Day 30), after two months (Day 60) and at the end of the 3 months of intervention (Day90). During those visits, the following were monitored: glucose parameters, lipids parameters, fatty acid profile of red blood cells and plasma and safety parameters related to haematology, kidney and liver functions .
During these monthly medical visits patients also completed the questionnaires assessing intestinal tolerance (visual analogue scale showing 10 gastrointestinal symptoms), satiety (visual analog scale questionnaire) and well-being (36 items short form survey). Eating habits were monitored using a food diary. Additional parameters were measured only during the first and the last visit: coagulation, nutritional status, endothelial function and inflammation.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
-
Louvain-La-Neuve, Бельгия, 1348
- Center of Investigation in Clinical Nutrition
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Woman or man, aged of 35 to 75 years
- Abdominal obesity : waist circumference for men > 94cm and > 80cm for women
- Practicing < 2h of physical activity per week
Exclusion Criteria:
- Uncontrolled systolic blood pressure > 160/100mmHg
- For premenopausal women: pregnant or lactating women
- For menopausal women: less than 6 months of menopause
- Perimenopausal women with symptoms
- Type II diabetes (fasted glycaemia ≥ 126mg/dl or HbA1c ≥ 6.5%), Type I diabetes
- Medical history or actual cardiovascular disease (myocardial infarction, angina, transient ischemic attack, lower limb arteriopathy)
- Familial history of premature cardiovascular incident (in male first degree relative < 55 years and in female first degree relative < 65 years; myocardial infarction, angina, transient ischemic attack, lower limb arteriopathy)
- Medical history or actual liver, pancreas, kidney, pulmonary or gastrointestinal problem
- Thyroid disorder
- Cancer < 5 years before the screening visit
- Smokers or who have stopped smoking within 6 months before the screening visit
- Subject presenting allergy or food intolerance to eggs
- Subjects with psychiatric problems and/or using antipsychotics
- Drug addiction problem
- Recent change of body weight > 5kg (< 3 months before the screening visit)
Within 3 months before the screening visit, change in the chronic (> 7 days in a row) intake or dosage of drug(s) or product(s) modifying
- The glucose or lipid metabolism
- The blood pressure and heart rate
- Intestinal tolerance
- Hepatic, pancreas or kidney functions
- Satiety
- The inflammatory status
- Current or recent (< 3 months before the screening visit) intake of dietary supplements rich in n-3 polyunsaturated fatty acid
- Vegan diet
- Consumption of fish > 3 times per week
- Subjects who drink more than 3 glasses of alcohol per day (> 30 g of alcohol per day)
- LDL > 159 mg/dl or total cholesterol > 239 mg/dl or triglyceride > 200 mg/dl or HDL < 40 mg/dl
- Docosahexaenoic acid in red blood cell phospholipids > 8 %
- Subjects having participated to another clinical trial < 1 month before the screening test visit
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Профилактика
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Двойной
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Плацебо Компаратор: Control
Consumption of two "classical eggs" per day during three months.
The fatty acid pattern of those eggs is characterized by: total saturated fatty acid 34.25%, total monounsaturated fatty acid 47.68%, total n-6 polyunsaturated fatty acid 16.97%, total n-3 polyunsaturated fatty acid 1.10%.
|
Consumption of two eggs (control or test) per day during three months
|
|
Экспериментальный: Test
Consumption of two test eggs per day during three months.
These eggs are naturally enriched in n-3 polyunsaturated fatty acids, conjugated-linoleic acids and conjugated-linolenic acids (total saturated fatty acid 31.74%,
total monounsaturated fatty acid 28.09%, total n-6 polyunsaturated fatty acid 16.07%, total n-3 polyunsaturated fatty acid 6.51%)
|
Consumption of two eggs (control or test) per day during three months
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Glycated haemoglobin (HbA1c)
Временное ограничение: Change from baseline (visit 1) glycated haemoglobin at 3 months (Day 90, visit 4)
|
Glycated haemoglobin (HbA1c) in blood samples
|
Change from baseline (visit 1) glycated haemoglobin at 3 months (Day 90, visit 4)
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Glucose
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Insulin
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Homeostatic model assessment (HOMA)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Quantitative insulin sensitivity check index (QUICKI)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Triglycerides
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Total cholesterol
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
low-density lipoprotein (LDL) cholesterol
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
high-density lipoprotein (HDL) cholesterol
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
non-high-density lipoprotein cholesterol (non-HDL)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fatty acid pattern in red blood cells
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fatty acid pattern plasma
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Urea
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Uric acid
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Creatinine
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Glomerular filtration rate (GFR)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Sodium (Na)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Potassium (K)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Chlore (Cl)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Phosphate (P)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Alanine transaminase (ALAT)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Aspartate aminotransferase (ASAT)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Gamma-glutamyl transferase (GGT)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Alkaline phosphatase (ALP)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Lipase
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Haemoglobin
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Mean corpuscular volume (MCV)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Mean corpuscular hemoglobin concentration (MCHC)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Red blood cells
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
White blood cells
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Blood cell count
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Reticulocytes
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Haematocrit
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Body weight
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Waist circumference
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Measuring tape
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Hip circumference
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Measuring tape
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Fat mass
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Lean mass
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Visceral fat mass
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
Impedancemeter
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
International normalized ratio (INR)
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Activated clotting time (ACT)
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Iron
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Transferrin
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Ferritin
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
% transferrin saturation
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Vitamin B12
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
25-hydroxy-vitamin D
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Protein
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Albumin
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
C-reactive protein (CRP)
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Interleukin-6
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Interleukin-1b
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Tumor necrosis factor alpha (TNFa)
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Oxidized low-density lipoprotein (LDLox)
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Nitrosylated hemoglobin (HbNO)
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
blood samples
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Satiety
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
visual analog scale questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Intestinal tolerance
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
visual analog scale questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Quality of life 36-item short-form survey (SF36)
Временное ограничение: baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
SF36 questionnaire
|
baseline (visit 1), Day 30 (visit 2), Day 60 (visit 3) and Day 90 (last visit 4)
|
|
Reactive hyperemia index (LnRHI)
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
Tonometry
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Augmentation index normalized for heart rate (AI@75bpm)
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
Tonometry
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Systolic blood pressure
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
Tensiometer
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Diastolic blood pressure
Временное ограничение: baseline (visit 1) and Day 90 (last visit 4)
|
Tensiometer
|
baseline (visit 1) and Day 90 (last visit 4)
|
|
Glycated haemoglobin (HbA1c)
Временное ограничение: Day 30 (visit 2) and Day 60 (visit 3)
|
Glycated haemoglobin in blood sample
|
Day 30 (visit 2) and Day 60 (visit 3)
|
Соавторы и исследователи
Спонсор
Следователи
- Директор по исследованиям: Yvan Larondelle, Prof, Université Catholique de Louvain
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- Oil4Egg
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .